Toge T, Ikeda H, Senoo N, Niimoto M, Hattori T
Jpn J Surg. 1976 Dec;6(4):157-63. doi: 10.1007/BF02468986.
The in vitro lymphocyte response to PHA was determined in patients with gastric cancer in various stages prior to the surgical treatment. The lymphocyte responsiveness in the presence of homologous pooled AB serum in patients of stages II, III and IV were markedly reduced as compared with that in healthy controls (stages II, III; p less than 0.05, stage IV; p less than 0.01). Inhibition of normal lymphocyte responsiveness to PHA by serum from patients in stages III and IV were statistically significant only in the advanced stage. It was concluded that the suppression of the immune response in the early stage of gastric cancer was mainly due to the impairment of lymphocyte itself, which advanced with the progress of the stage and was modified by the serum inhibitory effect in advanced stages. In patients with advanced cancer, the higher was the lymphocyte responsiveness to PHA and PWM prior to the initial treatment, the more effective was the immunotherapy. This shows that the indication of the immunotherapy in patients with advanced cancer could be initiated. Furthermore, the correlation between the lymphocyte responsiveness to PHA and the clinical results of immunotherapy was discussed.
在手术治疗前,对处于不同阶段的胃癌患者进行了体外淋巴细胞对PHA的反应性测定。与健康对照组相比,II期、III期和IV期患者在同源混合AB血清存在时的淋巴细胞反应性明显降低(II期、III期;p<0.05,IV期;p<0.01)。III期和IV期患者血清对正常淋巴细胞对PHA反应性的抑制仅在晚期具有统计学意义。得出的结论是,胃癌早期免疫反应的抑制主要是由于淋巴细胞自身的损伤,这种损伤随着病情进展而加重,并在晚期受到血清抑制作用的影响。在晚期癌症患者中,初始治疗前淋巴细胞对PHA和PWM的反应性越高,免疫治疗的效果就越好。这表明可以启动晚期癌症患者的免疫治疗指征。此外,还讨论了淋巴细胞对PHA的反应性与免疫治疗临床结果之间的相关性。